In this way, the actual effects that we obtain of the SGLT-2 inhibitors on the KCCQ in HF patients are simply the effects of the SGLT-2 inhibitors without the effects from the ejection fractions. This evidence concerns the gene SLC5A2 and hydrops fetalis.